

Gert J Lammers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9458100/publications.pdf>

Version: 2024-02-01

152
papers

13,247
citations

41344

49
h-index

22832

112
g-index

165
all docs

165
docs citations

165
times ranked

6212
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding the association between sleep, shift work and COVID-19 vaccine immune response efficacy: Protocol of the S-CORE study. <i>Journal of Sleep Research</i> , 2022, 31, e13496.	3.2	14
2	Comparing objective wakefulness and vigilance tests to on-the-road driving performance in narcolepsy and idiopathic hypersomnia. <i>Journal of Sleep Research</i> , 2022, 31, e13518.	3.2	7
3	Reduced Numbers of Corticotropin-Releasing Hormone Neurons in Narcolepsy Type 1. <i>Annals of Neurology</i> , 2022, 91, 282-288.	5.3	14
4	Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. <i>Sleep</i> , 2022, 45, .	1.1	10
5	“Sleepiness” in obstructive sleep apnea: getting into deep water. <i>Sleep Medicine</i> , 2022, 92, 64-66.	1.6	1
6	Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. <i>Sleep</i> , 2022, 45, .	1.1	5
7	Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification. <i>Sleep</i> , 2022, , .	1.1	2
8	Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea. <i>Human Psychopharmacology</i> , 2022, 37, .	1.5	8
9	New 2013 incidence peak in childhood narcolepsy: more than vaccination?. <i>Sleep</i> , 2021, 44, .	1.1	11
10	The tuberomammillary nucleus in neuropsychiatric disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 180, 389-400.	1.8	3
11	On-the-road driving performance of patients with central disorders of hypersomnolence. <i>Traffic Injury Prevention</i> , 2021, 22, 120-126.	1.4	2
12	Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays. <i>Clinical Biochemistry</i> , 2021, 90, 34-39.	1.9	9
13	European guideline and expert statements on the management of narcolepsy in adults and children. <i>European Journal of Neurology</i> , 2021, 28, 2815-2830.	3.3	67
14	European guideline and expert statements on the management of narcolepsy in adults and children. <i>Journal of Sleep Research</i> , 2021, 30, e13387.	3.2	44
15	Vigilance: discussion of related concepts and proposal for a definition. <i>Sleep Medicine</i> , 2021, 83, 175-181.	1.6	33
16	The orexin/hypocretin system in neuropsychiatric disorders: Relation to signs and symptoms. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 180, 343-358.	1.8	6
17	Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. <i>Sleep Medicine</i> , 2020, 67, 128-136.	1.6	182
18	Conventional autoantibodies against brain antigens are not routinely detectable in serum and CSF of narcolepsy type 1 and 2 patients. <i>Sleep Medicine</i> , 2020, 75, 188-191.	1.6	4

#	ARTICLE	IF	CITATIONS
19	The Sustained Attention to Response Task Shows Lower Cingulo-Opercular and Frontoparietal Activity in People with Narcolepsy Type 1: An fMRI Study on the Neural Regulation of Attention. <i>Brain Sciences</i> , 2020, 10, 419.	2.3	6
20	Reply to Micoulaud-Franchi etÂal. Commentary on diagnosis of central disorders of hypersomnolence: From clinic to clinic via ontology and semantic analysis on a bullet point path. <i>Sleep Medicine Reviews</i> , 2020, 52, 101329.	8.5	4
21	Effect of treatment on cognitive and attention problems in children with narcolepsy type 1. <i>Sleep</i> , 2020, 43, .	1.1	8
22	Reply to Maski K etÂal. commentary on diagnosis of central disorders of hypersomnolence: Challenges in defining central disorders of hypersomnolence. <i>Sleep Medicine Reviews</i> , 2020, 52, 101326.	8.5	4
23	HLA associations in narcolepsy type 1 persist after the 2009 H1N1 pandemic. <i>Journal of Neuroimmunology</i> , 2020, 342, 577210.	2.3	1
24	Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. <i>CNS Drugs</i> , 2020, 34, 773-784.	5.9	10
25	Daytime sleep state misperception in a tertiary sleep centre population. <i>Sleep Medicine</i> , 2020, 69, 78-84.	1.6	15
26	Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. <i>Sleep Medicine Reviews</i> , 2020, 52, 101306.	8.5	119
27	A Mobile App for Longterm Monitoring of Narcolepsy Symptoms: Design, Development, and Evaluation. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14939.	3.7	12
28	Widespread white matter connectivity abnormalities in narcolepsy type 1: A diffusion tensor imaging study. <i>NeuroImage: Clinical</i> , 2019, 24, 101963.	2.7	13
29	Narcolepsy â€” clinical spectrum, aetiopathophysiology, diagnosis and treatment. <i>Nature Reviews Neurology</i> , 2019, 15, 519-539.	10.1	364
30	The development of hypocretin deficiency in narcolepsy type 1 can be swift and closely linked to symptom onset: clues from a singular case. <i>Sleep</i> , 2019, 42, .	1.1	2
31	H1N1 hemagglutinin-specific HLA-DQ6-restricted CD4+ T cells can be readily detected in narcolepsy type 1 patients and healthy controls. <i>Journal of Neuroimmunology</i> , 2019, 332, 167-175.	2.3	15
32	Update on the Treatment of Idiopathic Hypersomnia. <i>Current Sleep Medicine Reports</i> , 2019, 5, 207-214.	1.4	6
33	Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. <i>Journal of Sleep Research</i> , 2019, 28, e12684.	3.2	18
34	Chronotypes and circadian timing in migraine. <i>Cephalalgia</i> , 2018, 38, 617-625.	3.9	60
35	Enhanced food-related responses in the ventral medial prefrontal cortex in narcolepsy type 1. <i>Scientific Reports</i> , 2018, 8, 16391.	3.3	12
36	Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 2071-2078.	3.6	36

#	ARTICLE	IF	CITATIONS
37	Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	90
38	Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning. <i>Scientific Reports</i> , 2018, 8, 10628.	3.3	36
39	Drugs Used in Narcolepsy and Other Hypersomnias. <i>Sleep Medicine Clinics</i> , 2018, 13, 183-189.	2.6	11
40	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines â€“ Multi-country assessment. <i>Vaccine</i> , 2018, 36, 6202-6211.	3.8	53
41	Sleep in 2016: methodological issues and progress. <i>Lancet Neurology</i> , The, 2017, 16, 15-17.	10.2	0
42	Eating Decisions Based on Alertness Levels After a Single Night of Sleep Manipulation: A Randomized Clinical Trial. <i>Sleep</i> , 2017, 40, .	1.1	14
43	Narcolepsy with cataplexy. , 2017, , .		0
44	Core Body and Skin Temperature in Type 1 Narcolepsy in Daily Life; Effects of Sodium Oxybate and Prediction of Sleep Attacks. <i>Sleep</i> , 2016, 39, 1941-1949.	1.1	12
45	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. <i>PLoS ONE</i> , 2016, 11, e0152390.	2.5	3
46	The European Narcolepsy Network (<sc>EU</sc>â€“<sc>NN</sc>) database. <i>Journal of Sleep Research</i> , 2016, 25, 356-364.	3.2	47
47	Improved vigilance after sodium oxybate treatment in narcolepsy: a comparison between inâ€“field and inâ€“laboratory measurements. <i>Journal of Sleep Research</i> , 2016, 25, 486-496.	3.2	20
48	Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias. <i>Expert Review of Vaccines</i> , 2016, 15, 573-584.	4.4	13
49	Bringing posttraumatic sleepâ€“wake disorders out of the dark. <i>Neurology</i> , 2016, 86, 1934-1935.	1.1	0
50	Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. <i>Sleep</i> , 2016, 39, 581-587.	1.1	66
51	Aberrant Food Choices after Satiation in Human Orexin-Deficient Narcolepsy Type 1. <i>Sleep</i> , 2016, 39, 1951-1959.	1.1	34
52	Restless legs syndrome in migraine patients: prevalence and severity. <i>European Journal of Neurology</i> , 2016, 23, 1110-1116.	3.3	25
53	Timeâ€“and stateâ€“dependent analysis of autonomic control in narcolepsy: higher heart rate with normal heart rate variability independent of sleep fragmentation. <i>Journal of Sleep Research</i> , 2015, 24, 206-214.	3.2	27
54	The effects of sodium oxybate on core body and skin temperature regulation in narcolepsy. <i>Journal of Sleep Research</i> , 2015, 24, 566-575.	3.2	9

#	ARTICLE	IF	CITATIONS
55	Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. <i>Sleep</i> , 2015, 38, 1051-1058.	1.1	49
56	Sleep-Mediated Heart Rate Variability after Bilateral Carotid Body Tumor Resection. <i>Sleep</i> , 2015, 38, 633-639.	1.1	7
57	Short-Term Effects of Electroconvulsive Therapy on Subjective and Actigraphy-Assessed Sleep Parameters in Severely Depressed Inpatients. <i>Depression Research and Treatment</i> , 2015, 2015, 1-7.	1.3	5
58	Neurology and psychiatry: waking up to opportunities of sleep. : State of the art and clinical/research priorities for the next decade. <i>European Journal of Neurology</i> , 2015, 22, 1337-1354.	3.3	46
59	Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. <i>Journal of Neuroimmunology</i> , 2015, 283, 58-62.	2.3	18
60	HLA dosage effect in narcolepsy with cataplexy. <i>Immunogenetics</i> , 2015, 67, 1-6.	2.4	18
61	Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index. <i>PLoS Genetics</i> , 2014, 10, e1004508.	3.5	80
62	Challenges in Diagnosing Narcolepsy without Cataplexy: A Consensus Statement. <i>Sleep</i> , 2014, 37, 1035-1042.	1.1	145
63	The influences of task repetition, napping, time of day, and instruction on the Sustained Attention to Response Task. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 1055-1065.	1.3	8
64	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. <i>European Journal of Endocrinology</i> , 2014, 171, 217-228.	3.7	33
65	Carotid body tumors are not associated with an increased risk for sleep-disordered breathing. <i>Sleep and Breathing</i> , 2014, 18, 103-109.	1.7	6
66	The MSLT: More Objections than Benefits as a Diagnostic Gold Standard?. <i>Sleep</i> , 2014, 37, 1027-1028.	1.1	19
67	Delusional Confusion of Dreaming and Reality in Narcolepsy. <i>Sleep</i> , 2014, 37, 419-422.	1.1	41
68	DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe. <i>Sleep</i> , 2014, 37, 19-25.	1.1	164
69	Glucose and Fat Metabolism in Narcolepsy and the Effect of Sodium Oxybate: A Hyperinsulinemic-Euglycemic Clamp Study. <i>Sleep</i> , 2014, 37, 795-801.	1.1	34
70	Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2013, 12, 1068-1075.	10.2	301
71	Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. <i>Vaccine</i> , 2013, 31, 994-1007.	3.8	58
72	A patient with narcolepsy with cataplexy and multiple sclerosis: two different diseases that may share pathophysiologic mechanisms?. <i>Sleep Medicine</i> , 2013, 14, 695-696.	1.6	14

#	ARTICLE	IF	CITATIONS
73	The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. <i>Vaccine</i> , 2013, 31, 1246-1254.	3.8	205
74	ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy. <i>PLoS Genetics</i> , 2013, 9, e1003270.	3.5	206
75	Plasma Total Ghrelin and Leptin Levels in Human Narcolepsy and Matched Healthy Controls: Basal Concentrations and Response to Sodium Oxybate. <i>Journal of Clinical Sleep Medicine</i> , 2013, 09, 797-803.	2.6	18
76	Altered Circadian Rhythm of Melatonin Concentrations in Hypocretin-Deficient Men. <i>Chronobiology International</i> , 2012, 29, 356-362.	2.0	9
77	Association between Hypocretin-1 and Amyloid- β ;42 Cerebrospinal Fluid Levels in Alzheimer's Disease and Healthy Controls. <i>Current Alzheimer Research</i> , 2012, 9, 1119-1125.	1.4	55
78	Hypocretin (orexin) loss in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1642-1650.	3.1	195
79	Severe fatigue in narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2012, 21, 163-169.	3.2	50
80	Sustained attention to response task (SART) shows impaired vigilance in a spectrum of disorders of excessive daytime sleepiness. <i>Journal of Sleep Research</i> , 2012, 21, 390-395.	3.2	61
81	A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2012, 21, 479-480.	3.2	27
82	The clinical features of cataplexy: A questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. <i>Sleep Medicine</i> , 2011, 12, 12-18.	1.6	121
83	Intranasal hypocretin-1: Making sense of scents?. <i>Sleep Medicine</i> , 2011, 12, 939-940.	1.6	3
84	Month of birth is not a risk factor for narcolepsy with cataplexy in the Netherlands. <i>Journal of Sleep Research</i> , 2011, 20, 522-525.	3.2	7
85	A Missense Mutation in Myelin Oligodendrocyte Glycoprotein as a Cause of Familial Narcolepsy with Cataplexy. <i>American Journal of Human Genetics</i> , 2011, 89, 474-479.	6.2	55
86	Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E1069-E1075.	3.5	24
87	Reward-Seeking Behavior in Human Narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2011, 07, 293-300.	2.6	50
88	Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. <i>Nature Genetics</i> , 2010, 42, 786-789.	21.4	170
89	Sodium oxybate is an effective and safe treatment for narcolepsy. <i>Sleep Medicine</i> , 2010, 11, 105-106.	1.6	29
90	Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. <i>General Hospital Psychiatry</i> , 2009, 31, 146-154.	2.4	76

#	ARTICLE	IF	CITATIONS
91	Hypocretin/orexin disturbances in neurological disorders. <i>Sleep Medicine Reviews</i> , 2009, 13, 9-22.	8.5	66
92	CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 487-489.	2.1	10
93	CSF hypocretin-1 levels are normal in multiple-system atrophy. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 342-344.	2.2	30
94	Narcolepsy: Immunological aspects. <i>Sleep Medicine Reviews</i> , 2008, 12, 95-107.	8.5	79
95	Manipulation of skin temperature improves nocturnal sleep in narcolepsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1354-1357.	1.9	45
96	Manipulation of Core Body and Skin Temperature Improves Vigilance and Maintenance of Wakefulness in Narcolepsy. <i>Sleep</i> , 2008, 31, 233-240.	1.1	70
97	Increased heart rate variability but normal resting metabolic rate in hypocretin/orexin-deficient human narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2008, 4, 248-54.	2.6	22
98	Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. <i>Brain</i> , 2007, 131, e88-e88.	7.6	39
99	Hypocretin (orexin) loss in Parkinson's disease. <i>Brain</i> , 2007, 130, 1577-1585.	7.6	407
100	Disorders of Sleep and Circadian Rhythms. , 2007, , 409-426.		1
101	High frequency repetitive transcranial magnetic stimulation over the motor cortex: No diagnostic value for narcolepsy/cataplexy. <i>Journal of Neurology</i> , 2007, 254, 1459-1461.	3.6	5
102	Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. <i>Journal of Neurology</i> , 2007, 254, 1607-1608.	3.6	54
103	Possible confusion between primary hypersomnia and adult attention-deficit/hyperactivity disorder. <i>Psychiatry Research</i> , 2006, 143, 293-297.	3.3	94
104	Cataplexy Leading to the Diagnosis of Niemann-Pick Disease Type C. <i>Pediatric Neurology</i> , 2006, 35, 82-84.	2.1	107
105	Altered Skin-Temperature Regulation in Narcolepsy Relates to Sleep Propensity. <i>Sleep</i> , 2006, 29, 1444-1449.	1.1	86
106	EFNS guidelines on management of narcolepsy. <i>European Journal of Neurology</i> , 2006, 13, 1035-1048.	3.3	235
107	Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. <i>Journal of Neuroimmunology</i> , 2006, 174, 187-191.	2.3	46
108	Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). <i>Sleep</i> , 2006, 29, 187-91.	1.1	49

#	ARTICLE	IF	CITATIONS
109	Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E892-E899.	3.5	34
110	The Number of Hypothalamic Hypocretin (Orexin) Neurons Is Not Affected in Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5466-5470.	3.6	87
111	Hypocretin/Orexin and Sleep. , 2005, , 279-290.		0
112	Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology, 2004, 62, 138-140.	1.1	125
113	Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. Journal of Sleep Research, 2004, 13, 257-264.	3.2	38
114	Is motor inhibition during laughter due to emotional or respiratory influences?. Psychophysiology, 2004, 41, 254-258.	2.4	26
115	Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience, 2004, 129, 727-732.	2.3	103
116	Pulsatile LH release is diminished, whereas FSH secretion is normal, in hypocretin-deficient narcoleptic men. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E630-E636.	3.5	51
117	Are Headache and Narcolepsy Associated?. Cephalalgia, 2003, 23, 775-775.	3.9	0
118	Hypocretin Deficiency in Narcoleptic Humans Is Associated with Abdominal Obesity. Obesity, 2003, 11, 1147-1154.	4.0	169
119	Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neuroscience Letters, 2003, 341, 13-16.	2.1	27
120	Pharmacological management of narcolepsy. Expert Opinion on Pharmacotherapy, 2003, 4, 1739-1746.	1.8	3
121	CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology, 2003, 61, 823-825.	1.1	97
122	Voxel-Based Morphometry in Hypocretin-Deficient Narcolepsy. Sleep, 2003, , .	1.1	19
123	Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E641-E647.	3.5	45
124	Voxel-based morphometry in hypocretin-deficient narcolepsy. Sleep, 2003, 26, 44-6.	1.1	58
125	The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias. Archives of Neurology, 2002, 59, 1553.	4.5	1,052
126	Dynamics of the Pituitary-Adrenal Ensemble in Hypocretin-Deficient Narcoleptic Humans: Blunted Basal Adrenocorticotropin Release and Evidence for Normal Time-Keeping by the Master Pacemaker. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5085-5091.	3.6	44

#	ARTICLE	IF	CITATIONS
127	Reduction of Plasma Leptin Levels and Loss of Its Circadian Rhythmicity in Hypocretin (Orexin)-Deficient Narcoleptic Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 805-809.	3.6	110
128	Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. <i>Neurology</i> , 2002, 58, 498-499.	1.1	133
129	Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. <i>Current Opinion in Neurology</i> , 2002, 15, 739-745.	3.6	31
130	Cataplexy: "tonic immobility" rather than "REM-sleep atonia"? <i>Sleep Medicine</i> , 2002, 3, 471-477.	1.6	45
131	Letter to the Editor. <i>Sleep Medicine</i> , 2002, 3, 531-532.	1.6	4
132	Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. <i>Current Opinion in Neurology</i> , 2002, 15, 739-745.	3.6	25
133	The hypothalamus in episodic brain disorders. <i>Lancet Neurology</i> , The, 2002, 1, 437-444.	10.2	59
134	Narcolepsy: Clinical Features, New Pathophysiologic Insights, and Future Perspectives. <i>Journal of Clinical Neurophysiology</i> , 2001, 18, 78-105.	1.7	318
135	CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. <i>Neurology</i> , 2001, 57, 2253-2258.	1.1	400
136	Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. <i>Annals of Neurology</i> , 2001, 50, 381-388.	5.3	451
137	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. <i>Nature Medicine</i> , 2000, 6, 991-997.	30.7	1,945
138	Hypocretin (orexin) deficiency in human narcolepsy. <i>Lancet</i> , The, 2000, 355, 39-40.	13.7	1,666
139	Effects of startle and laughter in cataplectic subjects: a neurophysiological study between attacks. <i>Clinical Neurophysiology</i> , 2000, 111, 1276-1281.	1.5	47
140	Weak with laughter. <i>Lancet</i> , The, 1999, 354, 838.	13.7	71
141	Clomipramine withdrawal in newborns. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 1999, 81, F77-F77.	2.8	19
142	Sleep Scoring at a Lower Resolution. <i>Sleep</i> , 1997, 20, 641-644.	1.1	2
143	Spontaneous Food Choice in Narcolepsy. <i>Sleep</i> , 1996, 19, 75-76.	1.1	119
144	Repetitive CMAPs: Mechanisms of neural and synaptic genesis. , 1996, 19, 1127-1133.		44

#	ARTICLE	IF	CITATIONS
145	Repetitive CMAPs: Mechanisms of neural and synaptic genesis. <i>Muscle and Nerve</i> , 1996, 19, 1127-1133.	2.2	2
146	Circadian distribution of motor activity and immobility in narcolepsy: Assessment with continuous motor activity monitoring. <i>Psychophysiology</i> , 1995, 32, 286-291.	2.4	44
147	Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study. <i>Sleep</i> , 1993, 16, 216-220.	1.1	184
148	The multiple sleep latency test: a paradoxical test?. <i>Clinical Neurology and Neurosurgery</i> , 1992, 94, 108-110.	1.4	16
149	Isolated Cataplexy of more than 40 Years' Duration. <i>British Journal of Psychiatry</i> , 1991, 159, 719-721.	2.8	7
150	Ritanserin, A 5-HT ₂ Receptor Blocker, as Add-on Treatment in Narcolepsy. <i>Sleep</i> , 1991, 14, 109-115.	1.1	34
151	Ritanserin, a 5-HT ₂ receptor blocker, as add-on treatment in narcolepsy. <i>Sleep</i> , 1991, 14, 130-2.	1.1	12
152	Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. <i>Nature and Science of Sleep</i> , 0, Volume 14, 1031-1047.	2.7	18